Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.

Yanagisawa S, Inoue A, Koarai A, Ono M, Tamai T, Ichinose M.

J Thorac Oncol. 2013 Aug;8(8):e73-4. doi: 10.1097/JTO.0b013e318293dfc1. No abstract available.

PMID:
23857405
2.

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.

Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M, Nakagawa K.

J Clin Oncol. 2013 Jan 1;31(1):e15-7. doi: 10.1200/JCO.2012.43.3730. Epub 2012 Nov 19. No abstract available.

3.

Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.

Watanabe N, Nakahara Y, Taniguchi H, Kimura T, Kondoh Y, Kataoka K, Sakamoto K.

Acta Oncol. 2014 Jan;53(1):158-60. doi: 10.3109/0284186X.2013.802838. Epub 2013 Jun 11. No abstract available.

PMID:
23750540
4.

Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease.

Tachihara M, Kobayashi K, Ishikawa Y, Hori S, Tamura D, Otera H, Funada Y, Nishimura Y.

Jpn J Clin Oncol. 2014 Aug;44(8):762-4. doi: 10.1093/jjco/hyu074. Epub 2014 May 28.

5.

Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.

Asai N, Yamaguchi E, Kubo A.

Clin Lung Cancer. 2014 May;15(3):e33-5. doi: 10.1016/j.cllc.2013.12.004. Epub 2013 Dec 27. No abstract available.

PMID:
24702855
6.

Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.

Chun SG, Iyengar P, Gerber DE, Hogan RN, Timmerman RD.

J Clin Oncol. 2015 Feb 10;33(5):e25-6. doi: 10.1200/JCO.2013.49.1985. Epub 2014 Mar 10. No abstract available.

7.

Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.

Pop O, Pirvu A, Toffart AC, Moro-Sibilot D.

J Thorac Oncol. 2012 Aug;7(8):e1-2. doi: 10.1097/JTO.0b013e318257fc1d. No abstract available.

PMID:
22797152
8.

Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.

Dallas JL, Jantz MA, Lightsey JL, Sonntag C, Kaye FJ.

J Thorac Oncol. 2011 Jun;6(6):1142-3. doi: 10.1097/JTO.0b013e318217b684. No abstract available.

PMID:
21623280
9.

Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.

Ji Y, Zhang Z, Nie K, Lan K, Geng C, Liu S, Zhang L, Zhang Z, Sun L, Zou X.

Chin Med J (Engl). 2014;127(8):1600. No abstract available.

10.

[Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer].

Toffart AC, Sakhri L, Moro-Sibilot D.

Rev Pneumol Clin. 2013 Apr;69(2):111-6. doi: 10.1016/j.pneumo.2012.11.010. Epub 2013 Apr 4. French.

PMID:
23561899
11.

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

Chiari R, Duranti S, Ludovini V, Bellezza G, Pireddu A, Minotti V, Bennati C, Crinò L.

J Clin Oncol. 2014 Mar 20;32(9):e30-2. doi: 10.1200/JCO.2012.47.7141. Epub 2014 Jan 13. No abstract available.

12.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L.

Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.cllc.2014.06.004. Epub 2014 Jun 24. No abstract available.

PMID:
25087901
13.

Crizotinib and renal insufficiency: a case report and review of the literature.

Martín Martorell P, Huerta Alvaro M, Solís Salguero MA, Insa Molla A.

Lung Cancer. 2014 Jun;84(3):310-3. doi: 10.1016/j.lungcan.2014.03.001. Epub 2014 Mar 12. Review.

PMID:
24703892
14.

Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.

Maillet D, Martel-Lafay I, Arpin D, Pérol M.

J Thorac Oncol. 2013 Apr;8(4):e30-1. doi: 10.1097/JTO.0b013e318288dc2d. No abstract available.

PMID:
23486270
15.

Clinical response to crizotinib retreatment after acquisition of drug resistance.

Matsuoka H, Kurata T, Okamoto I, Kaneda H, Tanaka K, Nakagawa K.

J Clin Oncol. 2013 Jul 1;31(19):e322-3. doi: 10.1200/JCO.2012.46.4305. Epub 2013 May 28. No abstract available.

16.

Widespread renal polycystosis induced by crizotinib.

Di Girolamo M, Paris I, Carbonetti F, Onesti EC, Socciarelli F, Marchetti P.

Tumori. 2015 Jul 24;101(4):e128-31. doi: 10.5301/tj.5000338.

PMID:
25953441
17.

Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.

Park J, Yoshida K, Kondo C, Shimizu J, Horio Y, Hijioka S, Hida T.

Lung Cancer. 2013 Sep;81(3):495-6. doi: 10.1016/j.lungcan.2013.06.017. Epub 2013 Jul 25.

PMID:
23891512
18.

Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose.

Ripault MP, Pinzani V, Fayolle V, Pageaux GP, Larrey D.

Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):e21-3. doi: 10.1016/j.clinre.2012.10.003. Epub 2012 Nov 20. No abstract available.

PMID:
23182672
19.

Crizotinib-associated erythema multiforme in a lung cancer patient.

Sawamura S, Kajihara I, Ichihara A, Fukushima S, Jinnin M, Yamaguchi E, Kohrogi H, Ihn H.

Drug Discov Ther. 2015 Apr;9(2):142-3. doi: 10.5582/ddt.2015.01019.

20.

Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status.

Tamai K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Katakami N, Tomii K.

Respir Investig. 2013 Mar;51(1):46-8. doi: 10.1016/j.resinv.2012.12.001. Epub 2013 Feb 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk